Neuroinflammation and sympathetic overactivity: Mechanisms and implications in hypertension

Autonomic Neuroscience: Basic and Clinical

Volumn 210, Issue , 2018, Pages 10-17

  Haspula, Dhanush ^a   Clark, Michelle A ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Brainstem; Hypertension; Neuroinflammation; Renin angiotensin system; Spontaneously hypertensive rats; Sympathetic activity

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINOCYCLINE; ANGIOTENSIN II; REACTIVE OXYGEN METABOLITE;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; HUMAN; HYPERTENSION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SYMPATHETIC OVERACTIVITY; SYMPATHETIC TONE; ANIMAL; AUTONOMIC NEUROPATHY; COMPLICATION; ENCEPHALITIS; GLIA; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II; ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; CYTOKINES; ENCEPHALITIS; HUMANS; HYPERTENSION; NEUROGLIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM;

EID: 85040632268     PISSN: 15660702     EISSN: 18727484     Source Type: Journal    
DOI: 10.1016/j.autneu.2018.01.002     Document Type: Review

References (150)

1. Abbott, N.J., Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200 (2002), 629–638.
2. Agarwal, D., Welsch, M.A., Keller, J.N., Francis, J., Chronic exercise modulates RAS components and improves balance between pro- and anti-inflammatory cytokines in the brain of SHR. Basic Res. Cardiol. 106 (2011), 1069–1085.
3. Aksamit, T.R., Floras, J.S., Victor, R.G., Aylward, P.E., Paroxysmal hypertension due to sinoaortic baroreceptor denervation in humans. Hypertension, 9, 1987.
4. Albaghdadi, M., Baroreflex control of long-term arterial pressure. Rev. Bras. Hipertens. 14 (2007), 212–225.
5. Allen, A.M., Inhibition of the hypothalamic paraventricular nucleus in spontaneously hypertensive rats dramatically reduces sympathetic vasomotor tone. Hypertension 39 (2002), 275–280 (Dallas, Tex.: 1979).
6. Anderson, E.A., Sinkey, C.A., Lawton, W.J., Mark, A.L., Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension 14 (1989), 177–183 (Dallas, Tex.: 1979).
7. Anderson, M.T., Staal, F.J., Gitler, C., Herzenberg, L.A., Herzenberg, L.A., Separation of oxidant-initiated and redox-regulated steps in the NF-kappa B signal transduction pathway. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 11527–11531.
8. Barbosa, R.M., Speretta, G.F., Dias, D.P.M., Ruchaya, P.J., Li, H., Menani, J.V., Sumners, C., Colombari, E., Colombari, D.S.A., Increased expression of macrophage migration inhibitory factor in the nucleus of the solitary tract attenuates renovascular hypertension in rats. Am. J. Hypertens. 30 (2017), 435–443.
9. Bátkai, S., Pacher, P., Osei-Hyiaman, D., Radaeva, S., Liu, J., Harvey-White, J., Offertáler, L. et al., Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110 (2004), 1996–2002.
10. Bélanger, M., Magistretti, P.J., The role of astroglia in neuroprotection. Dialogues Clin. Neurosci. 11 (2009), 281–295.
11. Biancardi, V.C., Stern, J.E., Compromised blood-brain barrier permeability: novel mechanism by which circulating angiotensin II signals to sympathoexcitatory centres during hypertension. J. Physiol. 594 (2016), 1591–1600.
12. Biancardi, V.C., Son, S.J., Ahmadi, S., Filosa, J.A., Stern, J.E., Circulating angiotensin II gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood-brain barrier. Hypertension 63 (2014), 572–579.
13. Biswas, S.K., Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox?. Oxidative Med. Cell. Longev., 2016(5698931), 2016.
14. Bodiga, V.L., Bodiga, S., Renin angiotensin system in cognitive function and dementia. Asian J. Neurosci. 2013 (2013), 1–18.
15. Bristow, J.D., Honour, A.J., Pickering, G.W., Sleight, P., Smyth, H.S., Diminished baroreflex sensitivity in high blood pressure. Circulation, 39, 1969.
16. Brooks, V.L., Sved, A.F., Pressure to change? Re-evaluating the role of baroreceptors in the long-term control of arterial pressure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 (2005), R815–8.
17. Brozoski, D.T., Dean, C., Hopp, F.A., Hillard, C.J., Seagard, J.L., Differential endocannabinoid regulation of baroreflex-evoked sympathoinhibition in normotensive versus hypertensive rats. Auton. Neurosci. 150 (2009), 82–93.
18. Busche, S., Gallinat, S., Fleegal, M.A., Raizada, M.K., Sumners, C., Novel role of macrophage migration inhibitory factor in angiotensin II regulation of neuromodulation in rat brain. Endocrinology 142 (2001), 4623–4630.
19. Calhoun, D.A., Jones, D., Textor, S., Goff, D.C., Murphy, T.P., Toto, R.D., White, A. et al., Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American heart association professional education committee of the council for high blood pressure research. Circulation 117 (2008), e510–e526.
20. Carlson, S.H., Wyss, J.M., Neurohormonal regulation of the sympathetic nervous system: new insights into central mechanisms of action. Curr. Hypertens. Rep. 10 (2008), 233–240.
21. Chapleau, M.W., Hajduczok, G., Abboud, F.M., Peripheral and central mechanisms of baroreflex resetting. Clin. Exp. Pharmacol. Physiol.(Suppl. 15), 1989, 31–43.
22. Chockalingam, A., Impact of world hypertension day. Can. J. Cardiol. 23 (2007), 517–519.
23. Cohen, D.L., Townsend, R.R., High rates of uncontrolled blood pressure in the United States: does this represent a missed opportunity for healthcare providers?. J. Clin. Hypertens., 15, 2013, 143.
24. Colombari, E., Sato, M.A., Cravo, S.L., Bergamaschi, C.T., Campos, R.R., Lopes, O.U., Role of the medulla oblongata in hypertension. Hypertension 38 (2001), 549–554 (Dallas, Tex.: 1979).
25. Cornish, K.G., Gilmore, J.P., Sino-aortic denervation in the monkey. J. Physiol. 360 (1985), 423–432.
26. Dampney, R.A., Functional organization of central pathways regulating the cardiovascular system. Physiol. Rev. 74 (1994), 323–364.
27. Dampney, R.A.L., Coleman, M.J., Fontes, M.A.P., Hirooka, Y., Horiuchi, J., Li, Y.W., Polson, J.W., Potts, P.D., Tagawa, T., Central mechanisms underlying short- and long-term regulation of the cardiovascular system. Clin. Exp. Pharmacol. Physiol. 29 (2002), 261–268.
28. Dange, R.B., Agarwal, D., Teruyama, R., Francis, J., Toll-like receptor 4 inhibition within the paraventricular nucleus attenuates blood pressure and inflammatory response in a genetic model of hypertension. J. Neuroinflammation, 12, 2015, 31.
29. Dembowsky, K., McAllen, R.M., Baroreceptor inhibition of subretrofacial neurons: evidence from intracellular recordings in the cat. Neurosci. Lett. 111 (1990), 139–143.
30. Dinh, Q.N., Drummond, G.R., Sobey, C.G., Chrissobolis, S., Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed. Res. Int. 2014 (2014), 1–11.
31. Doggrell, S.A., Brown, L., Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc. Res. 39 (1998), 89–105.
32. Esler, M., Jennings, G., Korner, P., Willett, I., Dudley, F., Hasking, G., Anderson, W., Lambert, G., Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 11 (1988), 3–20 (Dallas, Tex.: 1979).
33. Esler, M., Lambert, E., Schlaich, M., Point: chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension. J. Appl. Physiol. 109 (2010), 1996–1998 (Bethesda, Md.: 1985). (discussion 2016).
34. Fadl Elmula, F.E.M., Hoffmann, P., Larstorp, A.C., Fossum, E., Brekke, M., Kjeldsen, S.E., Gjonnaess, E. et al., Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 63 (2014), 991–999.
35. Fisher, J.P., Fadel, P.J., Therapeutic strategies for targeting excessive central sympathetic activation in human hypertension. Exp. Physiol. 95 (2010), 572–580.
36. Fisher, J.P., Paton, J.F.R., The sympathetic nervous system and blood pressure in humans: implications for hypertension. J. Hum. Hypertens. 26 (2012), 463–475.
37. Fisher, J.P., Young, C.N., Fadel, P.J., Central sympathetic overactivity: maladies and mechanisms. Auton. Neurosci. 148 (2009), 5–15.
38. Folkow, B., Physiological aspects of primary hypertension. Physiol. Rev. 62 (1982), 347–504.
39. Forette, F., Seux, M.-L., Staessen, J.A., Thijs, L., Babarskiene, M.-R., Babeanu, S., Bossini, A. et al., The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162 (2002), 2046–2052.
40. Freiria-Oliveira, A.H., Blanch, G.T., Li, H., Colombari, E., Colombari, D.S.A., Sumners, C., Macrophage migration inhibitory factor in the nucleus of solitary tract decreases blood pressure in SHRs. Cardiovasc. Res. 97 (2013), 153–160.
41. Fu, Q., Zhang, R., Witkowski, S., Arbab-Zadeh, A., Prasad, A., Okazaki, K., Levine, B.D., Persistent sympathetic activation during chronic antihypertensive therapy: a potential mechanism for long term morbidity?. Hypertension 45 (2005), 513–521.
42. Fyhrquist, F., Metsärinne, K., Tikkanen, I., Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J. Hum. Hypertens. 9:Suppl. 5 (1995), S19–24.
43. Gao, L., Wang, W., Li, Y.-L., Schultz, H.D., Liu, D., Cornish, K.G., Zucker, I.H., Sympathoexcitation by central ANG II: roles for AT1 receptor upregulation and NAD(P)H oxidase in RVLM. Am. J. Physiol. Heart Circ. Physiol., 288, 2005.
44. Gao, Y., O'Caoimh, R., Healy, L., Kerins, D.M., Eustace, J., Guyatt, G., Sammon, D., Molloy, D.W., Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open, 3, 2013, e002881.
45. Goldstein, D.S., Plasma catecholamines and essential hypertension. An analytical review. Hypertension 5 (1983), 86–99 (Dallas, Tex.: 1979).
46. Gowrisankar, Y.V., Clark, M.A., Angiotensin II induces interleukin-6 expression in astrocytes: role of reactive oxygen species and NF-κB. Mol. Cell. Endocrinol. 437 (2016), 130–147.
47. Graham, L.N., Smith, P.A., Huggett, R.J., Stoker, J.B., Mackintosh, A.F., Mary, D.A.S.G., Sympathetic drive in anterior and inferior uncomplicated acute myocardial infarction. Circulation, 109, 2004.
48. Grassi, G., Turri, C., Dell'Oro, R., Stella, M.L., Bolla, G.B., Mancia, G., Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. J. Hypertens. 16 (1998), 1789–1796.
49. Grassi, G., Dell'Oro, R., Quarti-Trevano, F., Scopelliti, F., Seravalle, G., Paleari, F., Gamba, P.L., Mancia, G., Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48 (2005), 1359–1365.
50. Grassi, G., Seravalle, G., Quarti-Trevano, F., The “neuroadrenergic hypothesis” in hypertension: current evidence. Exp. Physiol. 95 (2010), 581–586.
51. Guggilam, A., Patel, K.P., Haque, M., Ebenezer, P.J., Kapusta, D.R., Francis, J., Cytokine blockade attenuates sympathoexcitation in heart failure: cross-talk between nNOS, AT-1R and cytokines in the hypothalamic paraventricular nucleus. Eur. J. Heart Fail. 10 (2008), 625–634.
52. Guyenet, P.G., The sympathetic control of blood pressure. Nat. Rev. Neurosci. 7 (2006), 335–346.
53. Harrap, S.B., Van der Merwe, W.M., Griffin, S.A., Macpherson, F., Lever, A.F., Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 16 (1990), 603–614 (Dallas, Tex.: 1979).
54. Haspula, D., Clark, M.A., Heterologous regulation of the cannabinoid type 1 receptor by angiotensin II in astrocytes of spontaneously hypertensive rats. J. Neurochem. 139 (2016), 523–536.
55. Haspula, D., Clark, M., Regulation of neuroinflammatory cytokines by Angiotensin and Cannabinoid systems in SHR astrocytes. FASEB J., 31, 2017, lb554.
56. Haspula, D., Clark, M.A., MAPK activation patterns of AT1R and CB1R in SHR versus Wistar astrocytes: evidence of CB1R hypofunction and crosstalk between AT1R and CB1R. Cell. Signal. 40 (2017), 81–90.
57. Hermann, M., Ruschitzka, F., Novel anti-inflammatory drugs in hypertension. Nephrol. Dial. Transplant. 21 (2005), 859–864.
58. Hirooka, Y., Shigematsu, H., Kishi, T., Kimura, Y., Ueta, Y., Takeshita, A., Reduced nitric oxide synthase in the brainstem contributes to enhanced sympathetic drive in rats with heart failure. J. Cardiovasc. Pharmacol. 42:Suppl. 1 (2003), S111–5.
59. Ho, J.K., Nation, D.A., Memory is preserved in older adults taking AT1 receptor blockers. Alzheimers Res. Ther., 9(33), 2017.
60. Honzíková, N., Fišer, B., Honzíková, N., Baroreflex sensitivity and essential hypertension in adolescents. Physiol. Res. 58 (2009), 605–612.
61. Hu, L., Zhu, D.-N., Yu, Z., Wang, J.Q., Sun, Z.-J., Yao, T., Expression of angiotensin II type 1 (AT(1)) receptor in the rostral ventrolateral medulla in rats. J. Appl. Physiol. 92 (2002), 2153–2161.
62. Huggett, R.J., Scott, E.M., Gilbey, S.G., Stoker, J.B., Mackintosh, A.F., Mary, D.A.S.G., Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108 (2003), 3097–3101.
63. Isegawa, K., Hirooka, Y., Katsuki, M., Kishi, T., Sunagawa, K., Angiotensin II type 1 receptor expression in astrocytes is upregulated leading to increased mortality in mice with myocardial infarction-induced heart failure. Am. J. Physiol. Heart Circ. Physiol. 307 (2014), H1448–55.
64. Ito, S., Komatsu, K., Tsukamoto, K., Sved, A.F., Excitatory amino acids in the rostral ventrolateral medulla support blood pressure in spontaneously hypertensive rats. Hypertension 35 (2000), 413–417 (Dallas, Tex.: 1979).
65. Judy, W.V., Watanabe, A.M., Murphy, W.R., Aprison, B.S., Yu, P.L., Sympathetic nerve activity and blood pressure in normotensive backcross rats genetically related to the spontaneously hypertensive rat. Hypertension 1 (1979), 598–604.
66. Julius, S., Esler, M., Autonomic nervous cardiovascular regulation in borderline hypertension. Am. J. Cardiol. 36 (1975), 685–696.
67. Julius, S., Krause, L., Schork, N.J., Mejia, A.D., Jones, K.A., van de, Ven C., Johnson, E.H., Sekkarie, M.A., Kjeldsen, S.E., Petrin, J., Hyperkinetic borderline hypertension in Tecumseh, Michigan. J. Hypertens., 9, 1991, 77–84.
68. Kandalam, U., Clark, M.A., Angiotensin II activates JAK2/STAT3 pathway and induces interleukin-6 production in cultured rat brainstem astrocytes. Regul. Pept. 159 (2010), 110–116.
69. Kandalam, U., Sarmiento, N., Haspula, D., Clark, M.A., Angiotensin III induces signal transducer and activator of transcription 3 and interleukin-6 mRNA levels in cultured rat astrocytes. J. Renin-Angiotensin-Aldosterone Syst. 16 (2015), 758–767.
70. Kaplan, N.M., The control of hypertension: a therapeutic breakthrough. Am. Sci. 68 (1980), 537–545.
71. Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., He, J., Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005), 217–223.
72. Kishi, T., Hirooka, Y., Oxidative stress in the brain causes hypertension via sympathoexcitation. Front. Physiol., 3(335), 2012.
73. Kishi, T., Hirooka, Y., Sakai, K., Shigematsu, H., Shimokawa, H., Takeshita, A., Overexpression of eNOS in the RVLM causes hypotension and bradycardia via GABA release. Hypertension 38 (2001), 896–901 (Dallas, Tex.: 1979).
74. Kishi, T., Hirooka, Y., Ito, K., Sakai, K., Shimokawa, H., Takeshita, A., Cardiovascular effects of overexpression of endothelial nitric oxide synthase in the rostral ventrolateral medulla in stroke-prone spontaneously hypertensive rats. Hypertension 39 (2002), 264–268 (Dallas, Tex.: 1979).
75. Kishi, T., Hirooka, Y., Kimura, Y., Ito, K., Shimokawa, H., Takeshita, A., Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 109 (2004), 2357–2362.
76. Kishi, T., Hirooka, Y., Konno, S., Ogawa, K., Sunagawa, K., Angiotensin II type 1 receptor-activated Caspase-3 through Ras/mitogen-activated protein kinase/extracellular signal-regulated kinase in the rostral ventrolateral medulla is involved in sympathoexcitation in stroke-prone spontaneously hypertensive rats. Hypertension 55 (2010), 291–297.
77. Koldas, L., Ayan, F., Ikitimur, B., Short-term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist. Jpn. Heart J. 44 (2003), 693–704.
78. Korner, P.I., Circulatory control and the supercontrollers. J. Hypertens. 13 (1995), 1508–1521.
79. Korner, P., Bobik, A., Oddie, C., Friberg, P., Sympathoadrenal system is critical for structural changes in genetic hypertension. Hypertension 22 (1993), 243–252 (Dallas, Tex.: 1979).
80. Kougias, P., Weakley, S.M., Yao, Q., Lin, P.H., Chen, C., Arterial baroreceptors in the management of systemic hypertension. Med. Sci. Monit. 16 (2010), RA1–8.
81. Kumagai, H., Oshima, N., Matsuura, T., Iigaya, K., Imai, M., Onimaru, H., Sakata, K. et al., Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure. Hypertens. Res. 35 (2012), 132–141.
82. Laurent, S., Safar, M., Rilmenidine: a novel approach to first-line treatment of hypertension. Am. J. Hypertens. 5 (1992), 99S–105S.
83. Lehnardt, S., Massillon, L., Follett, P., Jensen, F.E., Ratan, R., Rosenberg, P.A., Volpe, J.J., Vartanian, T., Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. 100 (2003), 8514–8519.
84. Leimbach, W.N., Wallin, B.G., Victor, R.G., Aylward, P.E., Sundlöf, G., Mark, A.L., Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 73 (1986), 913–919.
85. Liu, G., Hosomi, N., Hitomi, H., Pelisch, N., Fu, H., Masugata, H., Murao, K., Ueno, M., Matsumoto, M., Nishiyama, A., Angiotensin II induces human astrocyte senescence through reactive oxygen species production. Hypertens. Res. 34 (2011), 479–483.
86. Lohmeier, T.E., Iliescu, R., The baroreflex as a long-term controller of arterial pressure. Physiology (Bethesda) 30 (2015), 148–158.
87. Lohmeier, T.E., Lohmeier, J.R., Warren, S., May, P.J., Cunningham, J.T., Sustained activation of the central baroreceptor pathway in angiotensin hypertension. Hypertension 39 (2002), 550–556.
88. Mancia, G., Ferrari, A., Leonetti, G., Pomidossi, G., Zanchetti, A., Carotid sinus baroreceptor control of arterial pressure in renovascular hypertensive subjects. Hypertension 4 (1982), 47–50 (Dallas, Tex.: 1979).
89. Mancia, G., Ferrari, A., Gregorini, L., Parati, G., Pomidossi, G., Bertinieri, G., Grassi, G., di Rienzo, M., Pedotti, A., Zanchetti, A., Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ. Res. 53 (1983), 96–104.
90. Mancia, G., Grassi, G., Giannattasio, C., Seravalle, G., Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34 (1999), 724–728 (Dallas, Tex.: 1979).
91. Marina, N., Tang, F., Figueiredo, M., Mastitskaya, S., Kasimov, V., Mohamed-Ali, V., Roloff, E., Teschemacher, A.G., Gourine, A.V., Kasparov, S., Purinergic signalling in the rostral ventro-lateral medulla controls sympathetic drive and contributes to the progression of heart failure following myocardial infarction in rats. Basic Res. Cardiol., 108(317), 2013.
92. Marina, N., Ang, R., Machhada, A., Kasymov, V., Karagiannis, A., Hosford, P.S., Mosienko, V. et al., Brainstem hypoxia contributes to the development of hypertension in the spontaneously hypertensive rat. Hypertension 65 (2015), 775–783.
93. Marvar, P.J., Lob, H., Vinh, A., Zarreen, F., Harrison, D.G., The central nervous system and inflammation in hypertension. Curr. Opin. Pharmacol. 11 (2011), 156–161.
94. Matsuura, T., Kumagai, H., Kawai, A., Onimaru, H., Imai, M., Oshima, N., Sakata, K., Saruta, T., Rostral ventrolateral medulla neurons of neonatal Wistar-Kyoto and spontaneously hypertensive rats. Hypertension 40 (2002), 560–565.
95. McGowan, C.L., Murai, H., Millar, P.J., Notarius, C.F., Morris, B.L., Floras, J.S., Simvastatin reduces sympathetic outflow and augments endothelium-independent dilation in non-hyperlipidaemic primary hypertension. Heart 99 (2013), 240–246.
96. McKaigue, J.P., Harron, D.W., The effects of rilmenidine on tests of autonomic function in humans. Clin. Pharmacol. Ther. 52 (1992), 511–517.
97. Mogi, M., Iwanami, J., Horiuchi, M., Roles of brain angiotensin II in cognitive function and dementia. Int. J. Hypertens. 2012 (2012), 1–7.
98. Muela, H.C.S., Costa-Hong, V.A., Yassuda, M.S., Moraes, N.C., Memória, C.M., Machado, M.F., Macedo, T.A. et al., Hypertension severity is associated with impaired cognitive performance. J. Am. Heart Assoc., 6, 2017.
99. Nagarkatti, P., Pandey, R., Rieder, S.A., Hegde, V.L., Nagarkatti, M., Cannabinoids as novel anti-inflammatory drugs. Future Med. Chem. 1 (2009), 1333–1349.
100. Negussie, S., Lymperopoulos, A., Clark, M.A., Unexpected negative role of the AT1R adaptor protein βarrestin1 in the ERK1/2 activation of SHR-derived primary astrocytes. FASEB J., 30, 2016, 719.6.
101. Nelson, L., Gard, P., Tabet, N., Hypertension and inflammation in Alzheimer's disease: close partners in disease development and progression!. J. Alzheimers Dis. 41 (2014), 331–343.
102. Nozoe, M., Hirooka, Y., Koga, Y., Araki, S., Konno, S., Kishi, T., Ide, T., Sunagawa, K., Mitochondria-derived reactive oxygen species mediate sympathoexcitation induced by angiotensin II in the rostral ventrolateral medulla. J. Hypertens. 26 (2008), 2176–2184.
103. Okuya, S., Inenaga, K., Kaneko, T., Yamashita, H., Angiotensin II sensitive neurons in the supraoptic nucleus, subfornical organ and anteroventral third ventricle of rats in vitro. Brain Res. 402 (1987), 58–67.
104. Oliveira-Sales, E.B., Colombari, E., Abdala, A.P., Campos, R.R., Paton, J.F.R., Sympathetic overactivity occurs before hypertension in the two-kidney, one-clip model. Exp. Physiol. 101 (2016), 67–80.
105. Osborn, J.W., Hypothesis: set-points and long-term control of arterial pressure. A theoretical argument for a long-term arterial pressure control system in the brain rather than the kidney. Clin. Exp. Pharmacol. Physiol. 32 (2005), 384–393.
106. Osborn, J.W., Fink, G.D., Region-specific changes in sympathetic nerve activity in angiotensin II-salt hypertension in the rat. Exp. Physiol. 95 (2010), 61–68.
107. Paton, J.F.R., Waki, H., Is neurogenic hypertension related to vascular inflammation of the brainstem?. Neurosci. Biobehav. Rev. 33 (2009), 89–94.
108. Pauletto, P., Rattazzi, M., Inflammation and hypertension: the search for a link. Nephrol. Dial. Transplant. 21 (2005), 850–853.
109. Pfützner, A., Marx, N., Lübben, G., Langenfeld, M., Walcher, D., Konrad, T., Forst, T., Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control. J. Am. Coll. Cardiol. 45 (2005), 1925–1931.
110. Reis, D.J., Experimental central neurogenic hypertension from brainstem dysfunction: evidence for a central neural imbalance hypothesis of hypertension. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 59 (1981), 229–257.
111. Saavedra, J., Grobecker, H., Axelrod, J., Adrenaline-forming enzyme in brainstem: elevation in genetic and experimental hypertension. Science 191 (1976), 483–484.
112. Safar, M.E., Weiss, Y.A., London, G.M., Frackowiak, R.F., Milliez, P.L., Cardiopulmonary blood volume in borderline hypertension. Clin. Sci. Mol. Med. 47 (1974), 153–164.
113. Sagara, J.I., Miura, K., Bannai, S., Maintenance of neuronal glutathione by glial cells. J. Neurochem. 61 (1993), 1672–1676.
114. Saito, M., Terui, N., Numao, Y., Kumada, M., Absence of sustained hypertension in sinoaortic-denervated rabbits. Am. J. Physiol. Heart Circ. Physiol., 251, 1986.
115. Salomone, S., Caraci, F., Leggio, G.M., Fedotova, J., Drago, F., New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br. J. Clin. Pharmacol. 73 (2012), 504–517.
116. Sandberg, K., Ji, H., Sex differences in primary hypertension. Biol. Sex Differ., 3, 2012, 7.
117. Sawicka, K., Szczyrek, M., Jastrzębska, I., Prasał, M., Zwolak, A., Daniluk, J., Hypertension – the silent killer. J. Pre-Clin. Clin. Res. 5 (2011), 43–46.
118. Shan, Z., Shi, P., Dong, Y., Lin, F., Lamont, G., Cuadra, A.E., Li, Q., Sumners, C., Raizada, M.K., Chronic reduction in paraventricular nucleus (PVN) AT1R expression by AAV-mediated transfer of a small hairpin RNA (shRNA) produces a decrease in blood pressure in spontaneously hypertensive rats. FASEB J., 25, 2011, 1027.7.
119. Shi, P., Diez-Freire, C., Jun, J.Y., Qi, Y., Katovich, M.J., Li, Q., Sriramula, S., Francis, J., Sumners, C., Raizada, M.K., Brain microglial cytokines in neurogenic hypertension. Hypertension 56 (2010), 297–303.
120. Shi, P., Raizada, M.K., Sumners, C., Brain cytokines as neuromodulators in cardiovascular control. Clin. Exp. Pharmacol. Physiol. 37 (2010), e52–7.
121. Shi, Z., Gan, X.-B., Fan, Z.-D., Zhang, F., Zhou, Y.-B., Gao, X.-Y., De, W., Zhu, G.-Q., Inflammatory cytokines in paraventricular nucleus modulate sympathetic activity and cardiac sympathetic afferent reflex in rats. Acta Physiol. 203 (2011), 289–297.
122. Skoog, I., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.A., Nilsson, L., Persson, G., Odén, A., Svanborg, A., 15-year longitudinal study of blood pressure and dementia. Lancet 347 (1996), 1141–1145.
123. Sleight, P., What is hypertension? Recent studies on neurogenic hypertension. Br. Heart J. 33 (1971), 109–112 Suppl.
124. Smith, P., Graham, L.N., Mackintosh, A.F., Stoker, J.B., Mary, D.A.S.G., Relationship between central sympathetic activity and stages of human hypertension. Am. J. Hypertens. 17 (2004), 217–222.
125. Stobart, J.L., Anderson, C.M., Multifunctional role of astrocytes as gatekeepers of neuronal energy supply. Front. Cell. Neurosci., 7(38), 2013.
126. Sun, C., Li, H., Leng, L., Raizada, M.K., Bucala, R., Sumners, C., Macrophage migration inhibitory factor: an intracellular inhibitor of angiotensin II-induced increases in neuronal activity. J. Neurosci. 24 (2004), 9944–9952.
127. Szabo, B., Imidazoline antihypertensive drugs: a critical review on their mechanism of action. Pharmacol. Ther. 93 (2002), 1–35.
128. Thrasher, T.N., Unloading arterial baroreceptors causes neurogenic hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282 (2002), R1044–53.
129. Thrasher, T.N., Baroreceptors, baroreceptor unloading, and the long-term control of blood pressure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 (2004), R819–R827.
130. Timmers, H.J.L.M., Wieling, W., Karemaker, J.M., Lenders, J.W.M., Denervation of carotid baro- and chemoreceptors in humans. J. Physiol. 553 (2003), 3–11.
131. Tonstad, S., Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutr. Metab. Cardiovasc. Dis. 16 (2006), 156–162.
132. Tsyrlin, V.A., Galagudza, M.M., Kuzmenko, N.V., Pliss, M.G., Rubanova, N.S., Shcherbin, Y.I., Arterial baroreceptor reflex counteracts long-term blood pressure increase in the rat model of renovascular hypertension. PLoS ONE, 8, 2013, e64788.
133. Tu, K., Chen, Z., Lipscombe, L.L., Canadian Hypertension Education Program Outcomes Research Taskforce for the C. H. E. P. O. R, Mortality among patients with hypertension from 1995 to 2005: a population-based study. CMAJ 178 (2008), 1436–1440.
134. Turlejski, T., Humoud, I., Desai, R., Smith, K.J., Marina, N., Immunohistochemical evidence of tissue hypoxia and astrogliosis in the rostral ventrolateral medulla of spontaneously hypertensive rats. Brain Res., 1650, 2016, 178.
135. Tzourio, C., Hypertension, cognitive decline, and dementia: an epidemiological perspective. Dialogues Clin. Neurosci. 9 (2007), 61–70.
136. Veerasingham, S.J., Raizada, M.K., Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives. Br. J. Pharmacol. 139 (2003), 191–202.
137. Wainford, R.D., Presympathetic neuron dysfunction - time to reconsider increased intrinsic activity as the cause of neurogenic hypertension. Exp. Physiol. 99 (2014), 935–936.
138. Waki, H., Central mechanisms of cardiovascular regulation during exercise: integrative functions of the nucleus of the solitary tract. J. Phys. Fitness Sports Med. 1 (2012), 253–261.
139. Waki, H., Gouraud, S.S., Brain Inflammation in Neurogenic Hypertension. 4, 2014, 1–6.
140. Waki, H., Gouraud, S.S., Maeda, M., Paton, J.F.R., Specific inflammatory condition in nucleus tractus solitarii of the SHR: novel insight for neurogenic hypertension?. Auton. Neurosci. 142 (2008), 25–31.
141. Waki, H., Gouraud, S.S., Maeda, M., Paton, J.F.R., Gene expression profiles of major cytokines in the nucleus tractus solitarii of the spontaneously hypertensive rat. Auton. Neurosci. 142 (2008), 40–44.
142. Waki, H., Gouraud, S.S., Maeda, M., Raizada, M.K., Paton, J.F.R., Contributions of vascular inflammation in the brainstem for neurogenic hypertension. Respir. Physiol. Neurobiol. 178 (2011), 422–428.
143. Weiss, L., Long-term treatment with antihypertensive drugs in spontaneously hypertensive rats (SHR). Effects on blood pressure, survival rate and cardiovascular design. Acta Physiol. Scand. 91 (1974), 393–408.
144. Widimsky, J., Fejfarova, M.H., Fejfar, Z., Changes of cardiac output in hypertensive disease. Cardiologia 31 (1957), 381–389.
145. Winklewski, P.J., Radkowski, M., Wszedybyl-Winklewska, M., Demkow, U., Brain inflammation and hypertension: the chicken or the egg?. J. Neuroinflammation, 12(85), 2015.
146. Wu, K.L., Chan, S.H., Chan, J.Y., Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. J. Neuroinflammation, 9(692), 2012.
147. Yao, L., Kan, E.M., Lu, J., Hao, A., Dheen, S.T., Kaur, C., Ling, E.-A., Toll-like receptor 4 mediates microglial activation and production of inflammatory mediators in neonatal rat brain following hypoxia: role of TLR4 in hypoxic microglia. J. Neuroinflammation, 10(23), 2013.
148. Zanutto, B.S., Valentinuzzi, M.E., Segura, E.T., Neural set point for the control of arterial pressure: role of the nucleus tractus solitarius. Biomed. Eng. Online, 9, 2010, 4.
149. Zhou, R., Yazdi, A.S., Menu, P., Tschopp, J., A role for mitochondria in NLRP3 inflammasome activation. Nature 469 (2011), 221–225.
150. Zhou, B., Bentham, J., Cesare, M., Di, Bixby H., Danaei, G., Cowan, M.J., Paciorek, C.J. et al., Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet 389 (2017), 37–55.